Original ArticleOpen Access
Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
Most recent
Romain Ramozzi, Nicolas Chéron, Laurent El Kaïm, Laurence Grimaud, Paul Fleurat-Lessard
- First Published: 15 January 2021
- https://doi.org/10.1111/abac.12246.pub2
This version
Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
Romain Ramozzi, Nicolas Chéron, Laurent El Kaïm, Laurence Grimaud, Paul Fleurat-Lessard
- First Published: 1 December 2020
- https://doi.org/10.1111/abac.12246
First published: 01 July 2021https://doi.org/10.1002/acr2.11259
Supported by UCB Pharma. Prof. Jeffrey R. Curtis has received grant/research support from Abbvie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo, Genentech, Janssen, Pfizer, Roche, and UCB Pharma. Dr. Xavier Mariette is supported by Biogen, Pfizer, and UCB Pharma. Dr. Boulos Haraoui has received grant/research support from Abbott, Amgen, Bristol-Myers Squibb, Janssen, Pfizer, Roche, and UCB Pharma.
Advertisement
